BCL3

BCL3 Full Name

B-cell CLL/lymphoma 3

BCL3 Introduction

BCL3, or B-cell CLL/lymphoma 3, is an atypical member of the IκB family of regulatory proteins best known for its role in modulating NF-κB transcriptional activity. Unlike classical IκBs that inhibit NF-κB in the cytoplasm, BCL3 primarily functions in the nucleus, where it interacts with p50 and p52 homodimers to regulate gene expression. First identified through its chromosomal translocation in certain B-cell leukemias, BCL3 has since been recognized as a multifunctional transcriptional co-regulator involved in immune signaling, cell survival, and differentiation. Its expression is responsive to inflammatory stimuli, cytokines, and oncogenic signals, positioning BCL3 at the intersection of immune regulation and cancer biology.

Figure 1. The mechanisms of action of BCL3 in immunology and cancer biology.

Functionally, BCL3 behaves as both a transcriptional activator and repressor depending on its binding partners and cellular context. It stabilizes p50/p52 NF-κB homodimers on DNA, recruits co-activators or co-repressors, and influences the expression of genes involved in cell proliferation, apoptosis resistance, and immune modulation. BCL3 contributes to lymphocyte development and activation, regulates inflammatory responses, and modulates pathways linked with metabolic stress and tissue remodeling. Experimental studies show that overexpression of BCL3 enhances cell survival signaling and promotes anchorage-independent growth, while its loss leads to impaired immune responses and altered NF-κB dynamics. These regulatory properties make BCL3 a key transcriptional node shaping how cells respond to environmental and inflammatory cues.

Clinically, dysregulated BCL3 expression is associated with several cancers and inflammatory diseases. It is frequently upregulated in B-cell chronic lymphocytic leukemia, Hodgkin lymphoma, breast cancer, colorectal cancer, and nasopharyngeal carcinoma, where it promotes tumor progression, metastasis, and therapy resistance through enhanced NF-κB signaling and altered transcriptional programs. BCL3 amplification or elevated expression often correlates with poor prognosis and aggressive tumor behavior. Beyond oncology, BCL3 has been implicated in autoimmune and inflammatory disorders due to its role in controlling cytokine expression and immune-cell activation. These disease associations highlight BCL3 as a biologically significant regulator of transcription, a potential biomarker of disease severity, and an emerging therapeutic target in cancer and immune-mediated pathologies.

Alternate Names for BCL3

BCL3; B-cell CLL/lymphoma 3; BCL4; D19S37; B-cell lymphoma 3 protein; BCL-3; proto-oncogene BCL3; B-cell leukemia/lymphoma 3; B-cell lymphoma 3-encoded protein; chronic lymphatic leukemia protein

• 1. Ai J,et al.; Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Gastroenterology. 2021, 161(1):318-332.e9.